Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Determine tumor response rate and time to disease progression, survival and safety in total populations.
Non-Small-Cell Lung Cancer
BIOLOGICAL: Cetuximab
The primary objective of this study was to determine the tumor response rate for single-agent cetuximab in EGFR+ subjects., Every 8 weeks
Determine the tumor response rate in the total population and in EGFR- subjects, Every 8 weeks|Time to disease progression in the EGFR+ and total populations., Every 8 weeks|Survival in the EGFR+ and total populations., Every 8 weeks|Safety in the EGFR+ and total populations., Every 8 weeks
To determine the tumor response rate and time to disease progression, survival and safety in the EGFR-positive, EGFR-negative and total populations.